Paper · 36965699

Cellular reprogramming of fibroblasts in heart regeneration.

Chi C and 1 other. J Mol Cell Cardiol, 2023. Cited by 14 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Cellular reprogramming of fibroblasts in heart regeneration. Papers, record 36965699. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36965699

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Cellular reprogramming of fibroblasts in heart regeneration.; PubMed
Journal: J Mol Cell Cardiol; PubMed
Year: 2023; PubMed
Publication types: Journal Article, Review, Research Support, N.I.H., Extramural; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/36965699/; PubMed
DOI: https://doi.org/10.1016/j.yjmcc.2023.03.009; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC10347886/; PubMed
The journal: https://conductscience.org/library/journal-index/0262322; PubMed
Citations, by iCite: 14; iCite
Relative citation ratio, by iCite: 1.55; iCite
Revised in PubMed: 2024-07-02; PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	Kind	ORCID iD
1	Chi C	Congwu
2	Song K	Kunhua

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Induced Pluripotent Stem Cells	Major topic
Heart Diseases	Major topic
Humans
Cellular Reprogramming
Myocytes, Cardiac
Fibroblasts

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
R01 HL133230	NHLBI NIH HHS	United States	R01HL133230	PubMed and NIH	NIH RePORTER
R01 HL159086	NHLBI NIH HHS	United States	R01HL159086	PubMed and NIH	NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References144

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	26,354,680	High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling.	Nat Commun	2015	https://conductscience.org/library/papers/26354680	PubMed
2	28,607,164	Cochrane Corner: stem cell therapy for chronic ischaemic heart disease and congestive heart failure.	Heart	2018	https://conductscience.org/library/papers/28607164	PubMed
3	26,942,852	Expandable Cardiovascular Progenitor Cells Reprogrammed from Fibroblasts.	Cell Stem Cell	2016	https://conductscience.org/library/papers/26942852	PubMed
4	23,222,518	Mammalian heart renewal by pre-existing cardiomyocytes.	Nature	2013	https://conductscience.org/library/papers/23222518	PubMed
5	34,193,613	Gene therapy knockdown of Hippo signaling induces cardiomyocyte renewal in pigs after myocardial infarction.	Sci Transl Med	2021	https://conductscience.org/library/papers/34193613	PubMed
6	26,942,853	Bmi1 Is a Key Epigenetic Barrier to Direct Cardiac Reprogramming.	Cell Stem Cell	2016	https://conductscience.org/library/papers/26942853	PubMed
7	28,527,533	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015.	J Am Coll Cardiol	2017	https://conductscience.org/library/papers/28527533	PubMed
8	23,168,164	Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes.	Cell Stem Cell	2013	https://conductscience.org/library/papers/23168164	PubMed
9	34,678,511	CRISPR activation of endogenous genes reprograms fibroblasts into cardiovascular progenitor cells for myocardial infarction therapy.	Mol Ther	2022	https://conductscience.org/library/papers/34678511	PubMed
10	23,642,535	Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes.	Biomaterials	2013	https://conductscience.org/library/papers/23642535	PubMed

1 to 10 of 144

See all 144 references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMID	Title	Journal	Year	In Papers	Source
42,972,466	Mechanobiology in cardiac regenerative medicine: from fundamental principles to therapeutic applications.	Stem Cell Res Ther	2026	https://conductscience.org/library/papers/42972466	PubMed
42,889,645	Britanin alleviates myocardial damage in rats with acute myocardial infarction by inhibiting the JAK2/STAT3 signaling pathway.	Iran J Basic Med Sci	2026	https://conductscience.org/library/papers/42889645	PubMed
42,459,194	Beyond cardiac fibroblasts: research advances on understanding and targeting intercellular communication networks in cardiac fibrosis.	Front Cardiovasc Med	2026	https://conductscience.org/library/papers/42459194	PubMed
40,756,129	Application of autologous stem cells in the treatment of ischaemic cardiomyopathy with heart failure after myocardial infarction.	J Stem Cells Regen Med	2025	https://conductscience.org/library/papers/40756129	PubMed
40,555,744	Cullin-associated and neddylation-dissociated protein 1 (CAND1) promotes cardiomyocyte proliferation and heart regeneration by enhancing the ubiquitinated degradation of Mps one binder kinase activator 1b (Mob1b).	Cell Death Differ	2025	https://conductscience.org/library/papers/40555744	PubMed
40,076,929	Hydrogels for Cardiac Tissue Regeneration: Current and Future Developments.	Int J Mol Sci	2025	https://conductscience.org/library/papers/40076929	PubMed
39,211,011	Cardiac tissue engineering: an emerging approach to the treatment of heart failure.	Front Bioeng Biotechnol	2024	https://conductscience.org/library/papers/39211011	PubMed
39,184,159	Myocardial Recovery versus Myocardial Regeneration: Mechanisms and Therapeutic Modulation.	Methodist Debakey Cardiovasc J	2024	https://conductscience.org/library/papers/39184159	PubMed
39,023,739	The Application of Mesenchymal Stem Cells in Different Cardiovascular Disorders: Ways of Administration, and the Effectors.	Stem Cell Rev Rep	2024	https://conductscience.org/library/papers/39023739	PubMed
38,334,642	Advances in the Generation of Constructed Cardiac Tissue Derived from Induced Pluripotent Stem Cells for Disease Modeling and Therapeutic Discovery.	Cells	2024	https://conductscience.org/library/papers/38334642	PubMed

1 to 10 of 11

See all 11 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36965699

GET https://conductscience.org/api/papers/v1/36965699/references?page=2

API reference For AI assistants